Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 22, 2026
TickeronGET DAILY SIGNALS
Dermata Therapeutics (DRMA) Stock Falls -36% Over 30 Days Amid Financing Pressures

Dermata Therapeutics (DRMA) Stock Falls -36% Over 30 Days Amid Financing Pressures

Key Takeaways

  • Dermata Therapeutics (DRMA) fell roughly 36% over the 30 days through mid-November, sliding from about $0.80 to approximately $0.51 per share.
  • The decline extends a longer downtrend: shares are down roughly 63% over the past quarter after peaking near $1.72 in late August.
  • Financing and dilution concerns, including a resale registration covering up to 6.92 million shares, pressured investor sentiment.
  • Dermata completed its pivot to a revenue-generating skincare business in Q3 2026 with the commercial launch of its Tome Foundational Treatment.
  • Positive cosmetic study results and the start of an acne-treatment clinical trial show pipeline progress, but early-stage execution and cash-runway risk remain key overhangs.
  • As a low-float micro-cap, DRMA is subject to sharp, liquidity-driven price swings.

Company Background and Transition to Commercial Operations

Dermata Therapeutics, Inc. is a San Diego-based dermatology company that has transitioned from a development-stage pharmaceutical firm into a direct-to-consumer skincare business. The company is building its commercial strategy around the Tome brand and its proprietary Bioneedle technology, a hero ingredient derived from 100% freshwater sponge that is wild-harvested and minimally processed into a fine, purified powder.

Dermata launched its first product, Tome Foundational Treatment, in August 2026 as a once-weekly skin-renewal treatment. It is advancing a second product, Tome Clearing Treatment, an over-the-counter acne treatment combining salicylic acid with Bioneedle. Investors follow DRMA for its early commercialization progress, its transition to recurring subscription revenue, and its ability to scale a differentiated brand in the competitive premium skincare market. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Stock Price Performance Over the Past 30 Days and Quarter

Over the 30 days ended mid-November, DRMA declined approximately 36%, falling from a closing price of about $0.80 in late October to roughly $0.51. The move was punctuated by elevated volume and steady selling pressure rather than a single-day collapse.

The quarterly picture is steeper. After a sharp run-up in August that carried shares to a peak near $1.72, the stock has retreated roughly 63% over the past three months. The downtrend reflects a fading of the mid-August speculative surge and the re-emergence of balance-sheet and dilution concerns as the dominant themes for this micro-cap name.

Factors Behind the Recent Price Decline

Several verified factors shaped the recent decline. On October 9, Dermata filed a registration statement covering the resale of up to 6.92 million shares by selling stockholders, a disclosure that reinforced concerns about potential supply overhang and dilution in a thinly traded, low-float stock.

Cash-runway risk also remained in focus. In its first-quarter filing, Dermata disclosed $6.9 million in cash and cash equivalents as of March 31, 2026, an accumulated deficit, and substantial doubt about its ability to continue as a going concern absent additional financing. While the company has since begun generating product revenue, its commercial operations are still early-stage.

The pullback also followed a period of unusually heavy trading. A burst of speculative activity in mid-October, including a single session with tens of millions of shares traded, gave way to a sustained decline as momentum faded. Positive operational news, including cosmetic study results and the start of an acne-treatment trial, was not enough to offset the financing-driven pressure on sentiment.

Quarterly Trends and Business Developments

The broader multi-month trend reflects a sharp reversal from August's speculative spike. Dermata's August 25 launch of Tome Foundational Treatment, priced at $178 for a four-treatment set, briefly energized the stock and lifted shares toward their peak. However, the rally was not sustained as attention shifted back to fundamentals.

Dermata's Q3 2026 results, reported November 10, confirmed the company's transition to a revenue-generating commercial skincare business and noted that roughly 30% of orders arrived through subscriptions. Yet the company remains pre-profitability, with modest initial revenue and ongoing marketing spend. The combination of limited float, recurring financing needs, and a still-uncertain path to scale has kept the stock under pressure throughout the quarter.

What Investors Should Watch Next

Looking ahead, investors should monitor Dermata's subscription growth and revenue trajectory for Tome Foundational Treatment, as well as progress on Tome Clearing Treatment, which the company expects to launch in the first half of 2027. Cash position and any new financing, equity, or warrant activity will remain central given the going-concern disclosures.

Consumer adoption, marketing efficiency, and competitive positioning in the premium skincare category are also key variables. Because DRMA is a low-float micro-cap, trading volumes and liquidity can amplify price movements. These are informational factors to track, not a basis for any specific investment decision.

AI Tools in Portfolio Monitoring

In my own work, I regularly review automated strategies through Tickeron’s AI Trading Bots to see how different approaches are performing on names like this. The platform lets users explore a range of data-driven signals and backtested scenarios that complement fundamental research, helping to put price action and volume patterns into broader context without replacing individual analysis.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: DRMA

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for DRMA turns negative, indicating new downward trend

DRMA saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 98 similar instances where the indicator turned negative. In 91 of the 98 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for DRMA turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 57 similar instances when the indicator turned negative. In 53 of the 57 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where DRMA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for DRMA entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.06% 3-day Advance, the price is estimated to grow further. Considering data from situations where DRMA advanced for three days, in 148 of 189 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

DRMA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.085) is normal, around the industry mean (3.596). P/E Ratio (-0.182) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. DRMA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DRMA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -9%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 70
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Industry
N/A
Address
3525 Del Mar Heights Road
Phone
+1 858 800-2543
Employees
9
Web
https://www.dermatarx.com
Interact to see
Advertisement
Alphabet Inc. (GOOG) , the parent of Google, YouTube, and Google Cloud, is a common stock, not an exchange-traded fund. The central target of $400 is the arithmetic mean of current analyst price targets, which span a wide band from roughly $300 to $500, with the broad average near $397.
AAPL has shown stronger relative performance in recent weeks, holding near record highs while many artificial intelligence (AI)-focused tech stocks sold off. MSFT has lagged the market and now trades below its 50-day moving average amid concerns over heavy AI infrastructure spending.
GOOG declined roughly 20% over the past 30 days, falling from about $331 to around $264 per share. The sell-off was triggered by Alphabet's third-quarter 2026 report, which revealed slowing Search advertising growth and an earnings miss.
Bending Spoons reported third-quarter 2026 revenue of $780.22 million, up 125.1% year over year and above the roughly $745.86 million consensus estimate. Earnings per share (EPS) came in at $0.42, beating the $0.26 consensus estimate by $0.16.
Intel Corporation has delivered dramatically stronger relative price momentum over the past year, while SPY offers broad, diversified market exposure with far lower single-stock volatility. INTC's rally has been driven by a strategic turnaround under new leadership, backed by multi-billion-dollar investments from Nvidia, SoftBank, and the U.S. government.